<!doctype html><html lang=zh-tw><head><meta charset=utf-8><meta name=description content="[!info]
🌱 來自: [[Huppert&rsquo;s Notes]]
 Arthridities #🚧 施工中 Arthridities Osteoarthritis (OA) • Pathogenesis: Progressive cartilage and meniscal degradation due to complex interplay of pathologic joint loading (due to obesity, joint malalignment, specific types of exercise or occupation, etc."><meta property="og:title" content><meta property="og:description" content><meta property="og:type" content="website"><meta property="og:url" content><meta property="og:image" content="https://og-ph6wrfvo1-htlin222.vercel.app/api/blog?templateTitle=Arthridities"><title>Arthridities</title><meta name=viewport content="width=device-width,initial-scale=1"><link rel="shortcut icon" type=image/png href=https://www.physician.tw//icon.png><link href=https://www.physician.tw/styles.547fb332ce56cdc523146ba5ede80d7f.min.css rel=stylesheet><link href=https://www.physician.tw/styles/_light_syntax.86a48a52faebeaaf42158b72922b1c90.min.css rel=stylesheet id=theme-link><script src=https://www.physician.tw/js/darkmode.dfadb738e747a87e78c7144d7267f1bc.min.js></script>
<script src=https://www.physician.tw/js/util.6f22941e242efae60fd84e7c32e874fa.min.js></script>
<link rel=preload href=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.css as=style onload='this.onload=null,this.rel="stylesheet"' integrity=sha384-R4558gYOUz8mP9YWpZJjofhk+zx0AS11p36HnD2ZKj/6JR5z27gSSULCNHIRReVs crossorigin=anonymous><script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.js integrity=sha384-z1fJDqw8ZApjGO3/unPWUPsIymfsJmyrDVWC8Tv/a1HeOtGmkwNd/7xUS0Xcnvsx crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/contrib/auto-render.min.js integrity=sha384-+XBljXPPiv+OzfbB3cVmLHf4hdUFHlWNZN5spNQ7rmHTXpd7WvJum6fIACpNNfIR crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.16.2/dist/contrib/copy-tex.min.js integrity=sha384-ww/583aHhxWkz5DEVn6OKtNiIaLi2iBRNZXfJRiY1Ai7tnJ9UXpEsyvOITVpTl4A crossorigin=anonymous></script>
<script async src=https://unpkg.com/@floating-ui/core@0.7.3></script>
<script async src=https://unpkg.com/@floating-ui/dom@0.5.4></script>
<script async src=https://www.physician.tw/js/popover.f03552ccb84d99ca615d1cfb9abde59e.min.js></script>
<script defer src=https://www.physician.tw/js/code-title.ce4a43f09239a9efb48fee342e8ef2df.min.js></script>
<script defer src=https://www.physician.tw/js/clipboard.2913da76d3cb21c5deaa4bae7da38c9f.min.js></script>
<script defer src=https://www.physician.tw/js/callouts.7723cac461d613d118ee8bb8216b9838.min.js></script>
<script>const SEARCH_ENABLED=!1,LATEX_ENABLED=!0,PRODUCTION=!0,BASE_URL="https://www.physician.tw/",fetchData=Promise.all([fetch("https://www.physician.tw/indices/linkIndex.d90a94e7d1436a79f0ef99c4db979265.min.json").then(e=>e.json()).then(e=>({index:e.index,links:e.links})),fetch("https://www.physician.tw/indices/contentIndex.4ecfe581d40745c9119f5f8ea5c00183.min.json").then(e=>e.json())]).then(([{index:e,links:t},n])=>({index:e,links:t,content:n})),render=()=>{const e=new URL(BASE_URL),t=e.pathname,n=window.location.pathname,s=t==n;addCopyButtons(),addTitleToCodeBlocks(),addCollapsibleCallouts(),initPopover("https://www.physician.tw",!0);const o=document.getElementById("footer");if(o){const e=document.getElementById("graph-container");if(!e)return requestAnimationFrame(render);e.textContent="";const t=s&&!1;drawGraph("https://www.physician.tw",t,[{"/moc":"#4388cc"}],t?{centerForce:1,depth:-1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.5,linkDistance:1,opacityScale:3,repelForce:1,scale:1.4}:{centerForce:1,depth:1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.6,linkDistance:1,opacityScale:3,repelForce:2,scale:1.2})}var i=document.getElementsByClassName("mermaid");i.length>0&&import("https://unpkg.com/mermaid@9/dist/mermaid.esm.min.mjs").then(e=>{e.default.init()})},init=(e=document)=>{addCopyButtons(),addTitleToCodeBlocks(),renderMathInElement(e.body,{delimiters:[{left:"$$",right:"$$",display:!0},{left:"$",right:"$",display:!1}],macros:{'’':"'"},throwOnError:!1})}</script><script type=module>
    import { attachSPARouting } from "https:\/\/www.physician.tw\/js\/router.9d4974281069e9ebb189f642ae1e3ca2.min.js"
    attachSPARouting(init, render)
  </script></head><body><div id=search-container><div id=search-space><input autocomplete=off id=search-bar name=search type=text aria-label=搜尋 placeholder="請輸入像是：hypertension 之類的來看沒有沒什麼有趣的🎳"><div id=results-container></div></div></div><script src=https://cdn.jsdelivr.net/npm/flexsearch@0.7.21/dist/flexsearch.bundle.js integrity="sha256-i3A0NZGkhsKjVMzFxv3ksk0DZh3aXqu0l49Bbh0MdjE=" crossorigin=anonymous defer></script>
<script defer src=https://www.physician.tw/js/full-text-search.e6e2e0c213187ca0c703d6e2c7a77fcd.min.js></script><div class=singlePage><header><h1 id=page-title><a href=https://www.physician.tw/>蜥蜴花園🦎🌱🪴🌲</a></h1><div class=spacer></div><div id=search-icon><p>搜尋</p><svg tabindex="0" aria-labelledby="title desc" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 19.9 19.7"><title id="title">搜尋圖示</title><desc id="desc">打開搜尋圖標</desc><g class="search-path" fill="none"><path stroke-linecap="square" d="M18.5 18.3l-5.4-5.4"/><circle cx="8" cy="8" r="7"/></g></svg></div><div class=darkmode><input class=toggle id=darkmode-toggle type=checkbox tabindex=-1>
<label id=toggle-label-light for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="dayIcon" viewBox="0 0 35 35" style="enable-background:new 0 0 35 35"><title>明亮模式</title><path d="M6 17.5C6 16.672 5.328 16 4.5 16h-3C.672 16 0 16.672.0 17.5S.672 19 1.5 19h3C5.328 19 6 18.328 6 17.5zM7.5 26c-.414.0-.789.168-1.061.439l-2 2C4.168 28.711 4 29.086 4 29.5 4 30.328 4.671 31 5.5 31c.414.0.789-.168 1.06-.44l2-2C8.832 28.289 9 27.914 9 27.5 9 26.672 8.329 26 7.5 26zm10-20C18.329 6 19 5.328 19 4.5v-3C19 .672 18.329.0 17.5.0S16 .672 16 1.5v3C16 5.328 16.671 6 17.5 6zm10 3c.414.0.789-.168 1.06-.439l2-2C30.832 6.289 31 5.914 31 5.5 31 4.672 30.329 4 29.5 4c-.414.0-.789.168-1.061.44l-2 2C26.168 6.711 26 7.086 26 7.5 26 8.328 26.671 9 27.5 9zM6.439 8.561C6.711 8.832 7.086 9 7.5 9 8.328 9 9 8.328 9 7.5c0-.414-.168-.789-.439-1.061l-2-2C6.289 4.168 5.914 4 5.5 4 4.672 4 4 4.672 4 5.5c0 .414.168.789.439 1.06l2 2.001zM33.5 16h-3c-.828.0-1.5.672-1.5 1.5s.672 1.5 1.5 1.5h3c.828.0 1.5-.672 1.5-1.5S34.328 16 33.5 16zM28.561 26.439C28.289 26.168 27.914 26 27.5 26c-.828.0-1.5.672-1.5 1.5.0.414.168.789.439 1.06l2 2C28.711 30.832 29.086 31 29.5 31c.828.0 1.5-.672 1.5-1.5.0-.414-.168-.789-.439-1.061l-2-2zM17.5 29c-.829.0-1.5.672-1.5 1.5v3c0 .828.671 1.5 1.5 1.5s1.5-.672 1.5-1.5v-3C19 29.672 18.329 29 17.5 29zm0-22C11.71 7 7 11.71 7 17.5S11.71 28 17.5 28 28 23.29 28 17.5 23.29 7 17.5 7zm0 18c-4.136.0-7.5-3.364-7.5-7.5s3.364-7.5 7.5-7.5 7.5 3.364 7.5 7.5S21.636 25 17.5 25z"/></svg></label><label id=toggle-label-dark for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="nightIcon" viewBox="0 0 100 100" style="enable-background='new 0 0 100 100'"><title>黑暗模式</title><path d="M96.76 66.458c-.853-.852-2.15-1.064-3.23-.534-6.063 2.991-12.858 4.571-19.655 4.571C62.022 70.495 50.88 65.88 42.5 57.5 29.043 44.043 25.658 23.536 34.076 6.47c.532-1.08.318-2.379-.534-3.23-.851-.852-2.15-1.064-3.23-.534-4.918 2.427-9.375 5.619-13.246 9.491-9.447 9.447-14.65 22.008-14.65 35.369.0 13.36 5.203 25.921 14.65 35.368s22.008 14.65 35.368 14.65c13.361.0 25.921-5.203 35.369-14.65 3.872-3.871 7.064-8.328 9.491-13.246C97.826 68.608 97.611 67.309 96.76 66.458z"/></svg></label></div></header><article><h1>Arthridities</h1><p class=meta>最後更新於
Jan 22, 2023
<a href=https://github.com/htlin222/garden/tree/hugo/content/Arthridities.md rel=noopener>🪚 編輯原始文件</a></p><ul class=tags></ul><blockquote class=info-callout><p></p><p>🌱 來自: <a class="internal-link broken">Huppert&rsquo;s Notes</a></p></blockquote><a href=#arthridities--施工中><h1 id=arthridities--施工中><span class=hanchor arialabel=Anchor># </span>Arthridities #🚧 施工中</h1></a><a href=#arthridities><h3 id=arthridities><span class=hanchor arialabel=Anchor># </span>Arthridities</h3></a><a href=#osteoarthritis-oa><h5 id=osteoarthritis-oa><span class=hanchor arialabel=Anchor># </span>Osteoarthritis (OA)</h5></a><p>•   Pathogenesis: Progressive cartilage and meniscal degradation due to complex interplay of pathologic joint loading (due to obesity, joint malalignment, specific types of exercise or occupation, etc.) and dysregulated joint repair processes.</p><p>•   Risk factors: Age >55 yr, female sex, obesity, acute or chronic joint injury</p><p>•   Clinical features and diagnosis:</p><p>-   OA is a clinical diagnosis made in a patient with compatible risk factors, joint pain that is worse with activity and relieved by rest, and absence of inflammatory features (e.g., absence of morning stiffness, absence of constitutional symptoms).</p><p>-   Joint effusions may occur (particularly in the knees) but the WBC count will be &lt;2K cells/μL.</p><p>-   Radiographic hallmarks include:</p><p><strong>•</strong>   Joint space narrowing</p><p><strong>•</strong>   Subchondral sclerosis (i.e., increased bone density deep to cartilage)</p><p><strong>•</strong>   Subchondral cysts</p><p><strong>•</strong>   Osteophytes</p><p><strong>•</strong>   No erosions (with the exception of inflammatory (or “erosive”) OA of the hand)</p><p>•   OA clinical phenotypes:</p><p>-   Primary OA: Most common; no identifiable secondary cause. Typical joints = hands (especially 1st CMC, DIPs, PIPs), hips, knees, and cervical and lumbar spine. Involvement may be asymmetric.</p><p>-   Secondary OA: Disease of the synovial joints resulting from a predisposing condition</p><p><strong>•</strong>   Local: Prior trauma (e.g., tibial plateau fracture), inflammatory/infectious arthritis or surgical intervention (e.g., ACL repair, meniscectomy) at the affected joint/joint space</p><p><strong>•</strong>   Systemic/metabolic: Hemochromatosis (2nd and 3rd MCPs and CMCs), hyperparathyroidism (wrists, MCPs), CPPD (MCPs, wrists, knees, hips), neuropathic arthropathy (such as in DM2), or OA-like pathologic changes accompanying inflammatory arthritis (such as psoriatic arthritis)</p><p>•   Inflammatory hand OA:</p><p>-   Associated with intermittent flares of swelling and redness of the affected joints (DIPs, PIPs) and erosions on hand X-ray</p><p>-   The erosions are characteristically found in the central joint space, as opposed to the marginal (peripheral) erosions seen in RA</p><p>-   Diffuse idiopathic skeletal hyperostosis (DISH): Characterized by calcification and ossification of the spinal ligaments and entheses, presenting with back pain and flowing osteophytes in the T spine on plain films (R side predominates in most cases)</p><p>•   Treatments:</p><p>-   Joint offloading: Work with occupational therapy/physical therapy to identify appropriate assistive devices (e.g., cane) or orthotics (e.g., thumb brace for 1st CMC OA)</p><p>-   Exercise to strengthen periarticular muscles (potentially guided by physical therapy)</p><p>-   Systemic and intra-articular pharmacotherapy (analgesic, not disease-modifying):</p><p><strong>•</strong>   NSAIDs</p><p><strong>•</strong>   Duloxetine</p><p><strong>•</strong>   Intraarticular glucocorticoids can be considered for knee and hip OA pain. Can be administered every 3 months (at which point pain relief effect tends to wane). No clear evidence of long-term harm with repeated injections, though one study showed an adverse effect on cartilage thickness (a finding that lacks any clear clinical correlate) (<strong>McAlindon et al. <em>JAMA</em> 2017</strong>).</p><p>-   Surgical therapy: Knee or hip joint replacement provides pain relief and improves function for patients who have failed conservative therapy</p><a href=#rheumatoid-arthritis-ra><h5 id=rheumatoid-arthritis-ra><span class=hanchor arialabel=Anchor># </span>Rheumatoid arthritis (RA)</h5></a><p>•   Pathogenesis: Mucosal inflammation triggers loss of tolerance to self-antigens in susceptible hosts, culminating in autoimmune destruction of synovial tissue.</p><p>•   Epidemiology and risk factors: 0.5–1% prevalence in the general population, F:M = ~3:1. Increased risk in patients with periodontal disease and those who smoke cigarettes.</p><p>•   Clinical features:</p><p>-   Symptoms:</p><p><strong>•</strong>   Typically AM stiffness that lasts one hour, improves with activity, and is aggravated by rest</p><p>-   Physical exam:</p><p><strong>•</strong>   Inflammatory polyarthritis with a predilection for the MCPs, PIPs, and MTPs with sparing of the DIPs of the upper and lower extremities. Variable involvement of the wrists, elbows, shoulders, hips, knees, ankles, and C-spine (characteristically involves the C1–C2 articulation; T- and L-spine are typically spared). Involvement is symmetric but severity may be asymmetric.</p><p><strong>•</strong>   Hand deformities: Ulnar deviation of MCP, Boutonniere deformities (contracture involving PIP flexion/DIP hyperextension), Swan-Neck deformity (contracture involving PIP hyperextension/DIP flexion)</p><p>-   Radiographic hallmarks (plain film):</p><p><strong>•</strong>   Periarticular osteopenia (earliest finding), symmetric joint space narrowing, erosions (typically at the medial and lateral joint margins including the ulnar styloid), and alignment deformities including subluxation and ulnar deviation of the MCPs</p><p>-   Lab findings:</p><p><strong>•</strong>   Rheumatoid factor (Rf; 50% patients have positive Rf in first 6 months; 75–85% by 2 yr)</p><p><strong>•</strong>   Anti-cyclic citrullinated peptide (CCP) antibodies: More specific than Rf (sensitivity 70%, specificity 95%)</p><p><strong>•</strong>   10–20% of cases are seronegative (e.g., Rf-negative, anti-CCP-negative)</p><p><strong>•</strong>   ESR and/or CRP is elevated in 75% of patients</p><p>-   Extra-articular manifestations:</p><p><strong>•</strong>   <strong>Derm:</strong> Rheumatoid nodules (30% of patients) occurring at pressure points including the olecranon; neutrophilic dermatoses including pyoderma gangrenosum and Sweet syndrome; small vessel cutaneous vasculitis may occur in patients with a history of smoking and/or longstanding RA</p><p><strong>•</strong>   <strong>Cardiac:</strong> Independent risk factor for CAD and CHF; pericarditis</p><p><strong>•</strong>   <strong>Pulm</strong>: Air trapping reflecting small airway inflammation in 50%, clinically apparent ILD in 10%; bronchiolitis; bronchiectasis; pleuritis (typically complicated exudative effusion with low pH/low glucose); cricoarytenoid arthritis (rare complication, presents with hoarseness, dysphagia, and stridor)</p><p><strong>•</strong>   <strong>Eyes:</strong> Sicca symptoms/secondary Sjögren’s; episcleritis; scleritis; keratitis</p><p><strong>•</strong>   <strong>CNS:</strong> Mononeuritis multiplex due to peripheral nerve entrapment; c-spine subluxation can lead to cervical myelopathy (rare)</p><p><strong>•</strong>   <strong>Heme:</strong> Anemia of inflammation; Felty syndrome (rare autoimmune condition characterized by the triad of neutropenia, splenomegaly, and longstanding seropositive RA); increased risk of large B cell lymphomas</p><p>•   Diagnosis: ACR/EULAR criteria: See Table 9.10.</p><p><strong>TABLE 9.10</strong> • Rheumatoid Arthritis Classification Criteria (2010 ACR/EULAR)</p><p>•   Symptom monitoring:</p><p>-   The Simplified Disease Activity Index (SDAI) incorporates tender and swollen joint counts, CRP level, and a clinician and patient-derived global assessment.</p><p>-   SDAI &lt;3.3 defines remission according to the ACR/EULAR guidelines.</p><p>•   Treatment:</p><p>-   Methotrexate is the first-line disease-modifying antirheumatic drug (DMARD)</p><p><strong>•</strong>   Titrate to the maximum tolerated dose (up to 25 mg weekly) at 12-week intervals</p><p><strong>•</strong>   At doses >15 mg weekly, consider subcutaneous dosing to improve bioavailability</p><p><strong>•</strong>   Contraindications to methotrexate include liver disease, advanced CKD, and heavy alcohol use</p><p><strong>•</strong>   Leflunomide can be used as first-line DMARD if there are contraindications to methotrexate use</p><p><strong>•</strong>   30–50% of paitents respond to methotrexate monotherapy</p><p>-   For patients who do not respond to methotrexate, consider adding:</p><p><strong>•</strong>   Sulfasalazine and hydroxychloroquine</p><p><strong>•</strong>   A TNF-α inhibitor</p><p><strong>•</strong>   Rituximab</p><p><strong>•</strong>   Tocilizumab</p><p><strong>•</strong>   Tofacitinib</p><p>-   Additional considerations:</p><p><strong>•</strong>   Prednisone 5–10 mg daily may be used to rapidly improve symptoms while awaiting therapeutic effect of disease modifying anti-rheumatic drugs (DMARDs)</p><p><strong>•</strong>   Methotrexate/hydroxychloroquine/sulfasalazine combination therapy may have similar efficacy to methotrexate and TNF-α inhibitor</p><p><strong>•</strong>   Patients with a very low SDAI score at diagnosis may be candidates for sulfasalazine or hydroxychloroquine monotherapy</p><p>-   Pregnancy:</p><p><strong>•</strong>   Pre-existing RA improves during pregnancy in 2/3 of cases and has a stable or worsening course in the other 1/3.</p><p><strong>•</strong>   Methotrexate and leflunomide are contraindicated in pregnancy</p><p><strong>•</strong>   Hydroxychloroquine and sulfasalazine are safe in pregnancy</p></article><hr><div class=page-end id=footer><div class=backlinks-container><h3>↩️ 反向連結</h3><ul class=backlinks><li><a href=/rheumatology-diseases-pathophysiology/ data-ctx=Arthridities data-src=/rheumatology-diseases-pathophysiology class=internal-link>rheumatology diseases & pathophysiology</a></li></ul></div><div><script async src=https://cdn.jsdelivr.net/npm/d3@6.7.0/dist/d3.min.js integrity="sha256-+7jaYCp29O1JusNWHaYtgUn6EhuP0VaFuswhNV06MyI=" crossorigin=anonymous></script><h3>🤯互動圖</h3><div id=graph-container></div><style>:root{--g-node:var(--secondary);--g-node-active:var(--primary);--g-node-inactive:var(--visited);--g-link:var(--outlinegray);--g-link-active:#5a7282}</style><script src=https://www.physician.tw/js/graph.2d9e48dbe7ea47c0ef1c58296ce14448.js></script></div></div><div><div id=disqus_thread></div><script type=application/javascript>window.disqus_config=function(){},function(){if(["localhost","127.0.0.1"].indexOf(window.location.hostname)!=-1){document.getElementById("disqus_thread").innerHTML="Disqus comments not available by default when the website is previewed locally.";return}var t=document,e=t.createElement("script");e.async=!0,e.src="//physician.disqus.com/embed.js",e.setAttribute("data-timestamp",+new Date),(t.head||t.body).appendChild(e)}()</script><noscript>Please enable JavaScript to view the <a href=https://disqus.com/?ref_noscript>comments powered by Disqus.</a></noscript><a href=https://disqus.com class=dsq-brlink>comments powered by <span class=logo-disqus>Disqus</span></a></div><div id=contact_buttons><footer><p>本網站是由 Hsieh-Ting Lin 以❤️ 用 <a href=https://github.com/jackyzha0/quartz>Quartz</a>這個酷東西種出來🪴 , © 2023</p><ul><li><a href=https://www.physician.tw/>🏠首頁</a></li><li><a href=https://www.facebook.com/Tim.H.Lin>Facebook</a></li><li><a href=https://twitter.com/htlin222>Twitter</a></li><li><a href=https://github.com/htlin222>GitHub</a></li><li><a href=https://htlin.site>Blog</a></li><li><a href=https://medium.com/@hsieh-ting-lin>Medium</a></li></ul></footer></div></div></body></html>